GlassScriptPhysician profile
Ronald L Chio
NPI 1780620823
$11,090.70
in general payments reported to CMS, 2019-2025
57 companies · $2,253 in 2025
The $2,253 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,664 · 2020: $980 · 2021: $1,482 · 2022: $1,334 · 2023: $1,507 · 2024: $1,870 · 2025: $2,253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,629.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,295.77 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,211.75 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,019.35 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Glaxosmithkline, LLC. | $954.88 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $889.38 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $824.88 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $439.09 | 2019-2025 | Repatha, Krystexxa, Repatha |
| Abbott Laboratories | $404.22 | 2019-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $355.94 | 2021-2025 | |
| Pfizer INC. | $347.18 | 2019-2025 | |
| Amarin Pharma, INC. | $278.13 | 2019-2022 | |
| Exact Sciences Corporation | $260.52 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $243.48 | 2019-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $208.97 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $189.54 | 2019-2023 | Trintellix |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Chio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.